Your browser is no longer supported. Please, upgrade your browser.
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
KALA [NASD]
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own1.29% Shs Outstand37.48M Perf Week-0.91%
Market Cap243.62M Forward P/E- EPS next Y-1.41 Insider Trans0.00% Shs Float33.97M Perf Month18.40%
Income-94.30M PEG- EPS next Q-0.56 Inst Own77.90% Short Float15.59% Perf Quarter75.20%
Sales6.10M P/S39.94 EPS this Y-10.60% Inst Trans-3.28% Short Ratio8.08 Perf Half Y61.69%
Book/sh0.85 P/B7.65 EPS next Y56.90% ROA-54.60% Target Price18.17 Perf Year-9.97%
Cash/sh2.28 P/C2.85 EPS next 5Y32.80% ROE-174.60% 52W Range3.24 - 9.25 Perf YTD76.15%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-87.40% 52W High-29.19% Beta-
Dividend %- Quick Ratio4.10 Sales past 5Y67.90% Gross Margin66.90% 52W Low102.16% ATR0.64
Employees136 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)56.54 Volatility8.48% 11.11%
OptionableYes Debt/Eq0.00 EPS Q/Q16.90% Profit Margin- Rel Volume0.74 Prev Close6.50
ShortableYes LT Debt/Eq2.40 EarningsFeb 12 BMO Payout- Avg Volume654.91K Price6.55
Recom1.70 SMA20-1.07% SMA5024.36% SMA20032.66% Volume485,905 Change0.77%
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Feb-12-20 11:30AM  Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year? Zacks
08:35AM  Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-09-20 03:22PM  The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight Benzinga
Feb-06-20 11:53AM  Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan Zacks +9.74%
08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call Business Wire
Feb-03-20 11:11AM  Aimmune's Palforzia Wins FDA Approval for Peanut Allergy Zacks +8.89%
Jan-30-20 11:10AM  Intercept (ICPT) Concludes Enrollment in Study on NASH Drug Zacks
Jan-22-20 09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks +5.30%
09:33AM  3 Healthcare Stocks With Important Catalysts in Q1 TipRanks
Jan-15-20 08:00AM  Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS (KPI-121 0.25%) for Dry Eye Disease Business Wire
Jan-14-20 09:21AM  Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 13% Simply Wall St.
Jan-08-20 08:00AM  Kala Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire +9.28%
Dec-19-19 09:53PM  Is Kala Pharmaceuticals, Inc. (KALA) A Good Stock To Buy? Insider Monkey
04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Dec-12-19 04:11PM  3 Biotech Stocks That Offer the Highest Upside on Wall Street TipRanks +12.86%
Nov-19-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-07-19 08:25AM  Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results Business Wire
Nov-04-19 04:30PM  Kala Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call Business Wire
Oct-21-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-11-19 08:34AM  What Kind Of Shareholders Own Kala Pharmaceuticals, Inc. (NASDAQ:KALA)? Simply Wall St.
Sep-25-19 08:40AM  Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Sep-19-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-29-19 08:00AM  Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September Business Wire
Aug-27-19 08:56AM  A Holistic Look At Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Simply Wall St. -6.54%
Aug-23-19 11:24AM  Keep Your Eye on These 4 Healthcare Stocks Motley Fool
Aug-20-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Aug-19-19 07:08AM  Should You Buy These 3 Beaten-Down Stocks Now? TipRanks
Aug-08-19 04:01PM  Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial Business Wire -9.98%
Aug-06-19 03:40PM  Kala Pharmaceuticals Reports Disappointing Q2 Sales Motley Fool -13.27%
02:23PM  Kala Pharmaceuticals, Inc. (KALA) Q2 2019 Earnings Call Transcript Motley Fool
09:45AM  Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM  Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results Business Wire
Jul-30-19 04:05PM  Kala Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call Business Wire
Jul-22-19 08:02AM  How Does Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Affect Your Portfolio Volatility? Simply Wall St.
Jun-20-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jun-13-19 03:11PM  Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven Simply Wall St.
May-30-19 08:00AM  Kala Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference Business Wire
May-17-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
May-16-19 02:15PM  Kala Pharmaceuticals, Inc. (KALA) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 08:15AM  Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:08AM  Kala Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports First Quarter 2019 Financial Results Business Wire
May-02-19 08:00AM  Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call Business Wire
Apr-29-19 08:59AM  Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock? Zacks
Apr-25-19 11:35AM  Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Down 52% Simply Wall St.
Apr-18-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Apr-01-19 08:00AM  Kala Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire
Mar-14-19 10:24AM  Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options Zacks
Mar-11-19 04:12PM  Kala Pharma: 4Q Earnings Snapshot Associated Press +6.03%
04:01PM  Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Business Wire
Mar-06-19 08:00AM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences in March Business Wire -7.92%
Mar-04-19 08:00AM  Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call Business Wire
Feb-22-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire +5.16%
Jan-18-19 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Jan-07-19 07:00AM  Kala Pharmaceuticals Announces the Launch of INVELTYS and the Hiring of a Specialty Ophthalmology Sales Organization Business Wire +6.17%
Jan-04-19 07:52AM  Kala Pharmaceuticals, Inc.s (NASDAQ:KALA) Path To Profitability Simply Wall St. +12.12%
Jan-02-19 08:00AM  Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference Business Wire +6.13%
Dec-28-18 07:20AM  Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-26-18 07:00AM  Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration Business Wire
Dec-19-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-23-18 08:00AM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Nov-08-18 07:56AM  Kala Pharma: 3Q Earnings Snapshot Associated Press
07:30AM  Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results Business Wire
Nov-07-18 04:05PM  Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference Business Wire
Oct-25-18 08:00AM  Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs Business Wire
Oct-24-18 08:55AM  New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire -10.19%
Oct-19-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Oct-18-18 08:00AM  Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO Business Wire
Oct-16-18 08:00AM  Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease Business Wire +10.94%
Oct-11-18 04:01PM  Kala Pharmaceuticals Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Oct-09-18 08:44AM  Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4% Zacks
Oct-03-18 11:58AM  Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today Motley Fool -15.52%
Oct-02-18 04:18PM  Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
04:18PM  Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million Business Wire
Sep-26-18 12:50PM  Is Kala Pharmaceuticals Incs (NASDAQ:KALA) Balance Sheet A Threat To Its Future? Simply Wall St. -8.09%
Sep-21-18 04:05PM  Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
Sep-10-18 02:17PM  Six Biotechnology Names on My Watch List TheStreet.com
Aug-31-18 07:50AM  Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:01PM  Kala Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
09:38AM  Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA Zacks
Aug-23-18 03:28PM  U.S. FDA approves Kala Pharma's eye pain drug Reuters -7.20%
02:13PM  Kala stock declines 6% after FDA approves ocular surgery product MarketWatch
Aug-16-18 10:06AM  H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date SmarterAnalyst +6.50%
Aug-09-18 07:48AM  Kala Pharma: 2Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results Business Wire
Aug-08-18 04:05PM  Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Aug-02-18 09:16PM  Kala Pharmaceuticals (KALA), Durect (DRRX), and Amarin (AMRN) Reiterated with a Buy at H.C. Wainwright SmarterAnalyst
Jul-31-18 08:00AM  Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease Business Wire
Jul-27-18 07:55AM  Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jul-23-18 07:28PM  According to H.C. Wainwright, This Biotech Stock Can Jump to $35 SmarterAnalyst
Jul-17-18 07:09AM  Kala Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-22-18 08:36AM  Options Traders Expect Huge Moves in Kala Pharmaceuticals (KALA) Stock Zacks
Jun-20-18 03:15PM  Wedbush Sees 240% Upside for Kala Pharmaceuticals (KALA) Stock; Heres Why SmarterAnalyst
Jun-19-18 04:01PM  Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan Business Wire
May-22-18 07:55AM  Market Trends Toward New Normal in Meredith, Weis Markets, Kala Pharmaceuticals, Fortress Transportation and Infrastructure Investors, Kraton, and Web.com Group Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-10-18 07:18AM  Kala Pharma: 1Q Earnings Snapshot Associated Press
07:00AM  Kala Pharmaceuticals Reports First Quarter 2018 Financial Results Business Wire
May-09-18 05:05PM  Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch Business Wire
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosen Howard BDirectorMay 30Buy5.425,00027,1008,240Jun 03 10:41 AM